SPERO THERAPEUTICS
Spero Therapeutics is developing first in class therapeutics for treatment of gram-negative infections. The company leverages a top-tier chemistry and microbiology team, an efficient virtual approach to drug development, and a focus on high potential, novel mechanisms to fill the unmet need for early stage therapeutics targeting serious bacterial infections. Its lead program addresses a novel target driving virulence and persistence of pseudomonas aeruginosa infections and other gram-negative pathogens.
SPERO THERAPEUTICS
Industry:
Biotechnology Medical Device Therapeutics
Founded:
2013-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.sperotherapeutics.com
Total Employee:
11+
Status:
Active
Contact:
+1 857 242 1600
Total Funding:
443.56 M USD
Technology used in webpage:
Domain Not Resolving Google Maps IPv6 COVID-19 DigiCert SSL Akamai Hosted RapidSSL
Similar Organizations
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
ForCast Orthopedics
ForCast Orthopedics, Inc is a medical device company with a significant goal to improve the treatment of orthopedic infections.
Imara
Imara is provider of novel therapeutics for the people living with sickle cell disease and hemoglobinopathies.
Neurovirt Limited
VR software, hardware, mobile App
Relavo
Novel device to prevent infection in peritoneal dialysis, a form of at-home treatment for end-stage renal disease.
Ribon Therapeutics
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Slingshot Biosciences
Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.
Tmunity Therapeutics
Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells
ZeroIN
ZeroIn is foodtech company developing next-gen sweeteners to help food and beverage manufacturers reduce sugar in their products.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
GlaxoSmithKline
GlaxoSmithKline investment in Post-IPO Equity - Spero Therapeutics
Biomedical Advanced Research and Development Authority (BARDA)
Biomedical Advanced Research and Development Authority (BARDA) investment in Grant - Spero Therapeutics
HealthCare Royalty Partners
HealthCare Royalty Partners investment in Post-IPO Debt - Spero Therapeutics
Pfizer
Pfizer investment in Post-IPO Equity - Spero Therapeutics
National Science Foundation
National Science Foundation investment in Grant - Spero Therapeutics
U.S. Department of Defense
U.S. Department of Defense investment in Grant - Spero Therapeutics
OUP (Osage University Partners)
OUP (Osage University Partners) investment in Post-IPO Equity - Spero Therapeutics
Cowen Investment Management
Cowen Investment Management investment in Post-IPO Equity - Spero Therapeutics
CARB-X
CARB-X investment in Grant - Spero Therapeutics
Google Ventures
Google Ventures investment in Series C - Spero Therapeutics
Key Employee Changes
Official Site Inspections
http://www.sperotherapeutics.com Semrush global rank: 1.1 M Semrush visits lastest month: 24.98 K
- Host name: aacb0a264e514dd48.awsglobalaccelerator.com
- IP address: 99.83.190.102
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "Spero Therapeutics"
About Us | Spero Therapeutics
Our team is fueled by a passion for the communities we serve and guided by the profound meaning of the Latin word “spero,” which encapsulates our vision: to bring hope to patients and caregivers alike who are grappling with the …See details»
Investor Relations - Spero Therapeutics
Nov 14, 2024 We are committed to promoting a diverse workforce, where all employees feel respected, valued, and empowered to contribute to our mission. We are actively working to …See details»
Meet Our Management Team | Spero Therapeutics
Meet the pioneers and emerging leaders in the anti-infective field at Spero Therapeutics. Get to know our experts in infectious disease treatment.See details»
Spero Therapeutics - Crunchbase Company Profile & Funding
Spero Therapeutics is developing first in class therapeutics for treatment of gram-negative infections. The company leverages a top-tier chemistry and microbiology team, an efficient …See details»
Spero Therapeutics - LinkedIn
Spero Therapeutics | 13,735 followers on LinkedIn. Multi-Asset, clinical-stage biotech company focused on multidrug-resistant bacterial infections and rare disease | We are a multi-asset, clinical ...See details»
Spero Therapeutics Announces $40 Million Equity Investment
CAMBRIDGE, Mass., June 30, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) – a multi-asset clinical-stage biopharmaceutical company focused on identifying, …See details»
Spero Therapeutics Announces First Patient, First Visit for Phase 3 ...
Jan 2, 2024 “First patient visit, in the PIVOT-PO Phase 3 clinical trial, is an important milestone in our tebipenem HBr program,” said Sath Shukla, President and CEO of Spero Therapeutics.See details»
Spero Therapeutics Provides Corporate Update and 2024 Outlook
Jan 5, 2024 Investor Relations Contact: Ted Jenkins Vice President, Investor Relations and Strategic [email protected] (617) 798-4039 Media Inquiries: Lora Grassilli , …See details»
Spero Therapeutics Announces Special Protocol Assessment …
Spero Therapeutics, Inc. Phase 3 PIVOT-PO trial is expected to begin with First Patient, First Visit in 4Q 2023. Spero to receive $30 million development milestone payment from GSK. …See details»
GSK and Spero Therapeutics announce exclusive licence …
Sep 22, 2022 In connection with the licence agreement and under a stock purchase agreement between GSK and Spero, GSK has agreed to make a $9 million investment in Spero common …See details»
Spero Therapeutics Announces New Strategic Direction Focusing …
May 3, 2022 Announces Immediate Cessation of Tebipenem HBr Commercialization Initiatives; Company to Shift Focus to Advancement of SPR720 and SPR206 Spero to Explore Strategic …See details»
Spero Therapeutics Announces SPR720 Phase 2a Interim Results …
Oct 29, 2024 “We are therefore suspending development of the SPR720 program and making adjustments to our organization accordingly. I want to offer my sincere thanks to all our Spero …See details»
SPRO.O - | Stock Price & Latest News | Reuters
Nov 19, 2024 Get Spero Therapeutics Inc (SPRO.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investmentsSee details»
Biopharmaceutical Jobs at Spero Therapeutics
Our experienced and uniquely qualified team of biotechnology and biopharmaceutical experts is led by President and CEO, Sath Shukla. Openly transparent and highly respectful, our …See details»
Spero Therapeutics Announces Clearance of IND for SPR206 to …
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and …See details»
Spero Therapeutics Announces FDA Acceptance and Priority
Jan 3, 2022 The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 27, 2022. January 03, 2022 08:05 ET | Source: Spero Therapeutics, Inc.See details»
Spero Therapeutics Announces First Patient Dosed with
Dec 10, 2020 Tuberculosis is a priority pathogen as defined by the World Health Organization with it being one of the top ten causes of death worldwide, and a situation where resistance is …See details»
Treating Antibiotic Resistance - Spero Therapeutics
Both the Centers for Disease Control (CDC) and World Health Organization (WHO) have identified antibiotic resistance as an increasing threat to global public health. Additionally, …See details»
Spero Therapeutics Announces SPR720 Phase 2a Interim Results …
Phase 2a proof-of-concept study of SPR720 for the treatment of Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) did not meet its primary endpoint, based on planned interim …See details»
Spero Therapeutics, Inc. (SPRO) - Stock Analysis
4 days ago Website https://sperotherapeutics.com. Full Company Profile. Financial Performance. Financial Statements. Analyst Forecast. According to 3 analysts, the average …See details»